08:33 AM EDT, 04/22/2024 (MT Newswires) -- Centessa Pharmaceuticals ( CNTA ) said Monday the US Food and Drug Administration has approved its investigational new drug application to begin a phase 1 clinical trial of ORX750, which is intended as a treatment of narcolepsy, a sleep disorder.

The phase 1 study will assess the safety, tolerability and pharmacokinetics of the drug candidate in healthy adult participants.

Dosing of the study is expected to begin imminently, the company said. Proof-of-concept data is expected in H2.